Anti-Polymyositis/Scl Antibodies in Systemic Sclerosis: Clinical Associations in a Multicentric Spanish Cohort and Review of the Literature.
Journal
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
ISSN: 1536-7355
Titre abrégé: J Clin Rheumatol
Pays: United States
ID NLM: 9518034
Informations de publication
Date de publication:
01 Jan 2022
01 Jan 2022
Historique:
pubmed:
4
5
2021
medline:
28
12
2021
entrez:
3
5
2021
Statut:
ppublish
Résumé
To assess the clinical profile of patients with anti-polymyositis/Scl (PM/Scl) antibodies in a cohort of Spanish patients with systemic sclerosis. From the Spanish Scleroderma Study Group database, we selected patients in whom PM/Scl antibodies had been tested. We compared demographic, clinical, laboratory, and survival data between patients with and without PM/Scl antibodies. Seventy-two of 947 patients (7.6%) tested positive for PM/Scl antibodies. Patients with PM/Scl antibodies presented initially with more puffy fingers and arthralgias but less Raynaud phenomenon. Regarding cumulative manifestations, myositis and arthritis were more prevalent in patients with PM/Scl antibodies, as well as pulmonary fibrosis. On the contrary, patients with PM/Scl antibodies had less pulmonary hypertension. No difference in terms of survival at 5 and 10 years was noticed between the 2 groups. In systemic sclerosis patients from Spain, PM/Scl antibodies are associated with a distinct clinical profile. However, PM/Scl antibodies did not influence survival.
Identifiants
pubmed: 33938499
doi: 10.1097/RHU.0000000000001676
pii: 00124743-202201000-00043
doi:
Substances chimiques
Antibodies
0
Autoantibodies
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e180-e188Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med . 2009;360:1989–2003.
Denton CP, Khanna D. Seminar systemic sclerosis. Lancet . 2017;6736:1–15.
Steen VD. The many faces of scleroderma. Rheum Dis Clin North Am . 2008;34:1–15.
Walker UA, Tyndall A, Czirják L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis . 2007;66:754–763.
Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, et al. Registry of the Spanish Network for Systemic Sclerosis: clinical pattern according to cutaneous subsets and immunological status. Semin Arthritis Rheum . 2012;41:789–800.
Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum . 2005;35:35–42.
Van Den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis . 2013;72:1747–1755.
Wolfe JF, Adelstein E, Sharp GC. Antinuclear antibody with distinct specificity for find the latest version: concise antinuclear antibody with distinct specificity for polymyositis. J Clin Invest . 1977;59:176–178.
Reichlin M, Maddison PJ, Targoff I, et al. Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes. J Clin Immunol . 1984;4:40–44.
Cepeda EJ, Reveille JD. Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance. Curr Opin Rheumatol . 2004;16:723–732.
Raijmakers R, Renz M, Wiemann C, et al. PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome. Arthritis Rheum . 2004;50:565–569.
Hanke K, Brückner CS, Dähnrich C, et al. Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res Ther . 2009;11:R22.
Ranque B, Bérezné A, Le-Guern V, et al. Myopathies related to systemic sclerosis: a case-control study of associated clinical and immunological features. Scand J Rheumatol . 2010;39:498–505.
Koschik RW 2nd, Fertig N, Lucas MR, et al. Anti–PM-Scl antibody in patients with systemic sclerosis. Clin Exp Rheumatol . 2012;30(2 Suppl 71):S12–S16.
Marguerie C, Bunn CC, Copier J, et al. The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore) . 1992;71:327–336.
Oddis CV, Okano Y, Rudert WA, et al. Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. Arthritis Rheum . 1992;35:1211–1217.
Vandergheynst F, Ocmant A, Sordet C, et al. Anti-PM/Scl antibodies in connective tissue disease: clinical and biological assessment of 14 patients. Clin Exp Rheumatol . 2006;24:129–133.
Alba MA, Velasco C, Simeón CP, et al., RESCLE Registry. Early- versus late-onset systemic sclerosis: differences in clinical presentation and outcome in 1037 patients. Medicine (Baltimore) . 2014;93:73–81.
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic And Therapeutic Criteria Committee. Arthritis Rheum . 1980;23:581–590.
LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol . 2001;28:1573–1576.
Alderuccio F, Chan EK, Tan EM. Molecular characterization of an autoantigen of PM-Scl in the polymyositis/scleroderma overlap syndrome: a unique and complete human cDNA encoding an apparent 75-kD acidic protein of the nucleolar complex. J Exp Med . 1991;173:941–952.
Ge Q, Frank MB, O'Brien C, et al. Cloning of a complementary DNA coding for the 100-kD antigenic protein of the PM-Scl autoantigen. J Clin Invest . 1992;90:559–570.
Gelpi C, Algueró A, Angeles Martinez M, et al. Identification of protein components reactive with anti-PM/Scl autoantibodies. Clin Exp Immunol . 1990;81:59–64.
Brouwer R, Vree Egberts WT, Hengstman GJ, et al. Autoantibodies directed to novel components of the PM/Scl complex, the human exosome. Arthritis Res . 2002;4:134–138.
Mahler M, Raijmakers R, Dähnrich C, et al. Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen. Arthritis Res Ther . 2005;7:R704–R713.
Raijmakers R, Egberts WV, Van Venrooij WJ, et al. The association of the human PM/Scl-75 autoantigen with the exosome is dependent on a newly identified N terminus. J Biol Chem . 2003;278:30698–30704.
Wodkowski M, Hudson M, Proudman S, et al. Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects. Autoimmunity . 2015;48:542–551.
Mierau R, Moinzadeh P, Riemekasten G, et al. Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther . 2011;13:R172.
D'Aoust J, Hudson M, Tatibouet S, et al., Canadian Scleroderma Research Group. Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. Arthritis Rheumatol . 2014;66:1608–1615.
Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol . 2010;6:112–116.
Mahler M, Fritzler MJ. PM1-alpha ELISA: the assay of choice for the detection of anti-PM/Scl autoantibodies? Autoimmun Rev . 2009;8:373–378.
Meyer O, De Chaisemartin L, Nicaise-Roland P, et al. Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study. J Rheumatol . 2010;37:125–130.
Walker UA, Tyndall A, Czirják L, et al. Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database. Ann Rheum Dis . 2009;68:856–862.
Villalta D, Imbastaro T, Di Giovanni S, et al. Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis. Autoimmun Rev . 2012;12:114–20.
Muro Y, Hosono Y, Sugiura K, et al. Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma. Arthritis Res Ter . 2015;17:57.
Maes L, Blockmans D, Verschueren P, et al. Anti-PM/Scl-100 and anti-RNA-polymerase III antibodies in scleroderma. Clin Chim Acta . 2010;411:965–71.